Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies

Aims A primary objective of this study was to investigate the effect of single and multiple doses of alisertib, an investigational Aurora A kinase inhibitor, on the QTc interval in patients with advanced malignancies. The dose regimen used was the maximum tolerated dose which was also the recommende...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Invest New Drugs
Egile Nagusiak: Zhou, Xiaofei, Nemunaitis, John, Pant, Shubham, Bauer, Todd M., Patel, Manish, Sarantopoulos, John, Craig Lockhart, A., Goodman, Daniel, Huebner, Dirk, Mould, Diane R., Venkatakrishnan, Karthik
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2017
Gaiak:
Phase I Studies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5869873/
https://ncbi.nlm.nih.gov/pubmed/28819760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0498-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak